Literature DB >> 1964819

Facilitation by 3,4-diaminopyridine of regenerative acetylcholine release from mouse motor nerve.

S J Hong1, C C Chang.   

Abstract

1. Effects of 3,4-diaminopyridine (DAP) on endplate potentials (e.p.ps) were studied in mouse phrenic nerve-hemidiaphragms. 2. In cut muscle preparations, low concentrations of DAP (2-20 microns) increased the amplitude of e.p.ps and shifted the curve relating Ca2+ concentration to e.p.p. amplitude leftward. 3. High concentration of DAP (40-4000 microns) prolonged the duration of e.p.ps dose-dependently up to one hundred fold (ca. 200 ms), yielding, in addition to the normal phasic e.p.p., a prolonged plateau depolarization component which was often preceded by an upstroke depolarization. During the plateau depolarization, nerve stimulations did not evoke any e.p.p. 4. The plateau component of prolonged e.p.ps was suppressed by tubocurarine, verapamil, nifedipine, Mn2+ and Cd2+ (but not by atropine) at low concentrations that had negligible effect on the amplitude of miniature e.p.ps or the phasic component of e.p.ps. Abolition of the plateau component by these agents restored the capability of the nerve terminal to evoke e.p.ps on nerve stimulation. 5. Low concentrations of neostigmine (0.01-0.02 microns) markedly lengthened DAP-prolonged e.p.ps. However, the regenerative endplate depolarization evoked in the presence of high concentrations of neostigmine (0.3-0.5 microns) was not prolonged by DAP. 6. Tetraethylammonium (1 mM) did not provoke prolonged e.p.ps but acted cooperatively with DAP to prolong the duration of plateau depolarization. At a high concentration (3 mM), tetraethylammonium depressed the amplitude of miniature e.p.ps and abolished DAP-prolonged e.p.ps. 7. In uncut muscle preparations, DAP apparently did not modify the time course and amplitude of miniature e.p.ps. Upon direct stimulation by current injection at endplate, DAP increased the muscle action potentials by only about 30%, but induced no prolonged depolarization. 8. These results suggest that the prolonged e.p.ps induced in the presence of DAP are due to a regenerative release of acetylcholine from motor nerve and the induction probably involves a presynaptic Ca2+ channel different from that for normal e.p.ps. It may be inferred that the regenerative acetylcholine release is recruited by Ca2 + channels modulated by nicotinic receptors and K+ channels.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1964819      PMCID: PMC1917818          DOI: 10.1111/j.1476-5381.1990.tb14159.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  31 in total

1.  Synaptic transmission in squid giant synapse after potassium conductance blockage with external 3- and 4-aminopyridine.

Authors:  R Llinás; K Walton; V Bohr
Journal:  Biophys J       Date:  1976-01       Impact factor: 4.033

2.  Factors affecting the time course of decay of end-plate currents: a possible cooperative action of acetylcholine on receptors at the frog neuromuscular junction.

Authors:  K L Magleby; D A Terrar
Journal:  J Physiol       Date:  1975-01       Impact factor: 5.182

3.  A comparison of the facilitatory actions of 4-aminopyridine methiodide and 4-aminopyridine on neuromuscular transmission.

Authors:  A S Horn; J J Lambert; I G Marshall
Journal:  Br J Pharmacol       Date:  1979-01       Impact factor: 8.739

4.  Effects of 4-aminopyridine on neuromuscular transmission.

Authors:  H Lundh
Journal:  Brain Res       Date:  1978-09-22       Impact factor: 3.252

5.  Effects of 4-aminopyridine on statistical parameters of transmitter release at the neuromuscular junction.

Authors:  H Lundh
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1979-05

6.  Synaptic vesicle exocytosis captured by quick freezing and correlated with quantal transmitter release.

Authors:  J E Heuser; T S Reese; M J Dennis; Y Jan; L Jan; L Evans
Journal:  J Cell Biol       Date:  1979-05       Impact factor: 10.539

7.  4-Aminopyridine and evoked transmitter release from motor nerve endings.

Authors:  P Illes; S Thesleff
Journal:  Br J Pharmacol       Date:  1978-12       Impact factor: 8.739

8.  Effects of low concentrations of 4-aminopyridine on CA1 pyramidal cells of the hippocampus.

Authors:  P Perreault; M Avoli
Journal:  J Neurophysiol       Date:  1989-05       Impact factor: 2.714

9.  The actions of three diaminopyridines on the chick biventer cervicis muscle.

Authors:  A L Harvey; I G Marshall
Journal:  Eur J Pharmacol       Date:  1977-08-15       Impact factor: 4.432

10.  The actions of aminopyridines on avian muscle.

Authors:  W C Bowman; A L Harvey; I G Marshall
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1977-03       Impact factor: 3.000

View more
  6 in total

1.  The upregulation of acetylcholine release at endplates of alpha-bungarotoxin-treated rats: its dependency on calcium.

Authors:  J J Plomp; G T van Kempen; P C Molenaar
Journal:  J Physiol       Date:  1994-07-01       Impact factor: 5.182

2.  Transmitter-mediated local contracture of the endplate region of the focally innervated mouse diaphragm treated with anticholinesterase.

Authors:  S J Hong; C C Chang
Journal:  Br J Pharmacol       Date:  1993-08       Impact factor: 8.739

3.  Pyridostigmine but not 3,4-diaminopyridine exacerbates ACh receptor loss and myasthenia induced in mice by muscle-specific kinase autoantibody.

Authors:  Marco Morsch; Stephen W Reddel; Nazanin Ghazanfari; Klaus V Toyka; William D Phillips
Journal:  J Physiol       Date:  2013-02-25       Impact factor: 5.182

Review 4.  Ca2+ channels as targets of neurological disease: Lambert-Eaton Syndrome and other Ca2+ channelopathies.

Authors:  Michael T Flink; William D Atchison
Journal:  J Bioenerg Biomembr       Date:  2003-12       Impact factor: 2.945

5.  Action of alpha-dendrotoxin on K+ currents in nerve terminal regions of axons in rat olfactory cortex.

Authors:  J McGivern; C N Scholfield; J O Dolly
Journal:  Br J Pharmacol       Date:  1993-06       Impact factor: 8.739

6.  Update on treatment options for Lambert-Eaton myasthenic syndrome: focus on use of amifampridine.

Authors:  Sabine Lindquist; Martin Stangel
Journal:  Neuropsychiatr Dis Treat       Date:  2011-05-30       Impact factor: 2.570

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.